Public Release: 

Study examines association between cholesterol-lowering drugs, memory impairment

The JAMA Network Journals

Both statin and nonstatin cholesterol-lowering drugs were associated with memory loss in the first 30 days after patients started taking the medications when compared with nonusers, but researchers suggest the association may have resulted because patients using the medications may have more contact with their physicians and therefore be more likely to detect any memory loss, according to an article published online by JAMA Internal Medicine.

Acute memory loss associated with the use of statins has been described in case reports and case studies, as well as in some studies, but the findings have been inconsistent and studies of long-term use of statins have found either improved memory or no effect.

Brian L. Strom, M.D., M.P.H., of Rutgers University, Newark, N.J., and co-authors used The Health Improvement Network (THIN) database, which is composed of the primary medical records from general practitioners in the United Kingdom, to compare 482,543 statin users with two control groups: 482,543 nonusers of any lipid-lowering drugs (LLDs) and 26,484 users of nonstatin LLDs (for example, cholestyramine, colestipol hydrochloride, colesevelam, clofibrate, gemfibrozil, fenofibrate and niacin). The authors also conducted a secondary case-crossover study. Diagnostic codes were used to gather data on memory loss.

The authors found that when comparing statin users to nonusers of any LLDs there was an increased risk of memory loss during the 30 days following the start of the medication, as well as increased risk in the first 30 days when comparing users of nonstatin LLDs with nonusers. That association was not there when comparing statins vs. nonstatin LLDs.

'This finding suggests that either all LLDs cause acute memory loss, or perhaps more likely, that the association is the results of detection bias,' the study concludes. Detection bias is the higher likelihood that memory loss will be ascertained in patients receiving preventive therapies, such as cholesterol-lowering medications, because they have increased contact with their physicians.


(JAMA Intern Med. Published online June 8, 2015. doi:10.1001/jamainternmed.2015.2092. Available pre-embargo to the media at

Editor's Note: Authors made conflict of interest disclosures. This study was supported by a grant from the National Institutes of Health. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.


Dory Devlin
908-872-6979 or email

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.